Comparative Pharmacology
Head-to-head clinical analysis: INDERIDE 80 25 versus VISKEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDERIDE 80 25 versus VISKEN.
INDERIDE-80/25 vs VISKEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
INDERIDE-80/25 is a combination of propranolol (a non-selective beta-adrenergic receptor antagonist) and hydrochlorothiazide (a thiazide diuretic). Propranolol blocks beta-1 and beta-2 adrenergic receptors, reducing heart rate, myocardial contractility, and renin release, thereby lowering blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the kidney, increasing excretion of sodium, chloride, and water, reducing plasma volume.
Non-selective beta-adrenergic receptor antagonist; competitively blocks beta1- and beta2-adrenergic receptors, decreasing heart rate, myocardial contractility, and blood pressure.
One tablet (80 mg propranolol/25 mg hydrochlorothiazide) orally twice daily.
5 mg orally twice daily, titrated to 10-20 mg twice daily based on response.
None Documented
None Documented
Propranolol: 3-6 hours (single dose), prolonged with chronic dosing (up to 12 hours). Hydrochlorothiazide: 6-15 hours; prolonged in renal impairment.
Terminal elimination half-life: 10-12 hours in healthy adults; prolonged to 20-40 hours in significant renal impairment.
Renal: 40% unchanged propranolol; 60% as metabolites. Biliary/fecal: minimal (less than 1%). Hydrochlorothiazide: renal 95% unchanged.
Renal (60-70% unchanged) and fecal (30-40% via biliary excretion as metabolites).
Category C
Category C
Beta Blocker and Thiazide Diuretic
Beta Blocker